Suprachoroidal Injection of CLS-TA in Subjects Non-infectious Uveitis

This is a Phase 3, open-label, multi-center study to assess the safety of 4 mg of CLS-TA
administered via suprachoroidal injection for the treatment of subjects with non-infectious
uveitis.

Inclusion Criteria:

- Diagnosis of non-infectious uveitis (pan, anterior, intermediate and posterior)

- ETDRS BCVA score of ≥ 5 letters read in the study eye

Exclusion Criteria:

- Any active ocular disease or infection in the study eye other than uveitis

- Intraocular pressure > 22 mmHg or uncontrolled glaucoma in the study eye

- Any uncontrolled systemic disease that, in the opinion of the Investigator, would
preclude participation in the study